ABBVIE INC. vs. Amylyx Pharmaceuticals, Inc. Common Stock
ABBVIE INC. (ABBV) comes out ahead, leading on 4 of 7 compared factors.
Size & Scale
| ABBV | AMLX | |
|---|---|---|
| Market Cap | $467.12 billion | $3.76 billion |
| Revenue (TTM) | $64.39 billion | — |
| Net Income (TTM) | $6.32 billion | $-152,092,000 |
ABBV leads on 3 of 3 size & scale factors.
Valuation
| ABBV | AMLX | |
|---|---|---|
| P/E Ratio | 74.67 | — |
| Price / Book | -79.33 | 15.74 |
| Price / Sales | 7.25 | — |
ABBV leads on 1 of 1 valuation factors.
Profitability
| ABBV | AMLX | |
|---|---|---|
| Net Margin | 9.81% | — |
| Return on Equity | -107.29% | -63.59% |
AMLX leads on 1 of 1 profitability factors.
Dividend
| ABBV | AMLX | |
|---|---|---|
| Dividend Yield | 2.62% | 5.69% |
| Payout Ratio | 195.48 | — |
AMLX leads on 1 of 1 dividend factors.
Risk & Sentiment
| ABBV | AMLX | |
|---|---|---|
| Short Interest | 0.85% | 0.00% |
AMLX leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, AMLX overview, AMLX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.